JP2023522250A5 - - Google Patents

Info

Publication number
JP2023522250A5
JP2023522250A5 JP2022564007A JP2022564007A JP2023522250A5 JP 2023522250 A5 JP2023522250 A5 JP 2023522250A5 JP 2022564007 A JP2022564007 A JP 2022564007A JP 2022564007 A JP2022564007 A JP 2022564007A JP 2023522250 A5 JP2023522250 A5 JP 2023522250A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522250A (ja
JP7663603B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/060167 external-priority patent/WO2021214019A1/en
Publication of JP2023522250A publication Critical patent/JP2023522250A/ja
Publication of JP2023522250A5 publication Critical patent/JP2023522250A5/ja
Priority to JP2025062751A priority Critical patent/JP7906937B2/ja
Application granted granted Critical
Publication of JP7663603B2 publication Critical patent/JP7663603B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564007A 2020-04-24 2021-04-20 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類 Active JP7663603B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025062751A JP7906937B2 (ja) 2020-04-24 2025-04-04 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20171280.9 2020-04-24
EP20171280 2020-04-24
PCT/EP2021/060167 WO2021214019A1 (en) 2020-04-24 2021-04-20 Substituted aminothiazoles as dgkzeta inhibitors for immune activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025062751A Division JP7906937B2 (ja) 2020-04-24 2025-04-04 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類

Publications (3)

Publication Number Publication Date
JP2023522250A JP2023522250A (ja) 2023-05-29
JP2023522250A5 true JP2023522250A5 (cg-RX-API-DMAC7.html) 2025-02-25
JP7663603B2 JP7663603B2 (ja) 2025-04-16

Family

ID=70464845

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022564009A Pending JP2023522251A (ja) 2020-04-24 2021-04-20 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類
JP2022564007A Active JP7663603B2 (ja) 2020-04-24 2021-04-20 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022564009A Pending JP2023522251A (ja) 2020-04-24 2021-04-20 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類

Country Status (32)

Country Link
US (3) US12673927B2 (cg-RX-API-DMAC7.html)
EP (2) EP4139286B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522251A (cg-RX-API-DMAC7.html)
KR (1) KR20230005247A (cg-RX-API-DMAC7.html)
CN (6) CN120093741A (cg-RX-API-DMAC7.html)
AR (1) AR121929A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021261524A1 (cg-RX-API-DMAC7.html)
CA (2) CA3180670A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002919A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014876A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220536A (cg-RX-API-DMAC7.html)
DK (1) DK4139286T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2022000223A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080829A (cg-RX-API-DMAC7.html)
ES (1) ES3029140T3 (cg-RX-API-DMAC7.html)
FI (1) FI4139286T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20257731B (cg-RX-API-DMAC7.html)
HR (1) HRP20250519T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071024T2 (cg-RX-API-DMAC7.html)
IL (1) IL297499A (cg-RX-API-DMAC7.html)
JO (1) JOP20220267A1 (cg-RX-API-DMAC7.html)
LT (1) LT4139286T (cg-RX-API-DMAC7.html)
MA (1) MA59379B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022013388A (cg-RX-API-DMAC7.html)
PE (1) PE20230322A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552828A1 (cg-RX-API-DMAC7.html)
PL (1) PL4139286T3 (cg-RX-API-DMAC7.html)
PT (1) PT4139286T (cg-RX-API-DMAC7.html)
RS (1) RS66889B1 (cg-RX-API-DMAC7.html)
SI (1) SI4139286T1 (cg-RX-API-DMAC7.html)
TW (1) TWI894261B (cg-RX-API-DMAC7.html)
WO (2) WO2021214019A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
AR120896A1 (es) 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CA3180670A1 (en) 2020-04-24 2021-10-28 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2022114164A1 (ja) 2020-11-30 2022-06-02 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117510497A (zh) * 2022-07-29 2024-02-06 山东轩竹医药科技有限公司 DGKζ抑制剂
KR20250046309A (ko) * 2022-08-08 2025-04-02 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN120957975A (zh) 2023-03-31 2025-11-14 拜耳公司 (r)-2-(n-[4-氨基-5-(4-甲氧基苯甲酰基)噻唑-2-基]-4-氟-苯胺基)丙酰胺的微晶形式及其制备方法
WO2024208198A1 (zh) * 2023-04-06 2024-10-10 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的噻唑类化合物
WO2024235203A1 (zh) * 2023-05-15 2024-11-21 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物
WO2025061020A1 (zh) * 2023-09-21 2025-03-27 楚浦创制(武汉)医药科技有限公司 苯并五元杂环衍生物及其制备方法与应用、药物组合物
WO2025067360A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 一种DGKzeta拮抗剂及其在医药上的应用
CN121586707A (zh) * 2023-10-17 2026-02-27 楚浦创制(武汉)医药科技有限公司 硫代羰基化合物及其应用
WO2025082460A1 (zh) * 2023-10-20 2025-04-24 上海先祥医药科技有限公司 二酰基甘油激酶抑制剂化合物及其应用
WO2025167814A1 (zh) * 2024-02-06 2025-08-14 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物
WO2026068294A1 (en) * 2024-09-24 2026-04-02 Bayer Aktiengesellschaft Improved nanoseeding process

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
US20040132124A1 (en) 2002-03-22 2004-07-08 Prescott Stephen M. Neuroprotection by inhibition of diacyglycerol kinase epsilon activity
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
US20050137239A1 (en) 2003-12-17 2005-06-23 Hines Michelle D. Thiazole derivatives
NZ550114A (en) 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
JP2007533730A (ja) 2004-04-20 2007-11-22 アブ サイエンス 筋炎および筋ジストロフィーを含む炎症性筋疾患を処置するためのc−kit阻害剤の使用法
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
US20080004279A1 (en) 2004-04-23 2008-01-03 Alain Moussy Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases
EP1742633A2 (en) 2004-04-23 2007-01-17 AB Science Use of c-kit inhibitors for treating fibrosis
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン,インコーポレーテッド Pde4b阻害剤及びその使用
US20070249628A1 (en) 2004-05-18 2007-10-25 Alain Moussy Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007022415A2 (en) 2005-08-18 2007-02-22 Pharmacopeia, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
KR100903974B1 (ko) 2007-09-27 2009-06-25 한국화학연구원 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 spc 수용체 활성으로 유발되는 염증관련 질환치료제
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CN102056483A (zh) 2008-06-03 2011-05-11 西佳技术公司 用于治疗或预防登革病毒感染的小分子抑制剂
JP5322296B2 (ja) 2008-08-20 2013-10-23 日本曹達株式会社 テトラゾイルオキシム誘導体を含む植物病害防除剤の使用方法
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2013033037A2 (en) 2011-08-26 2013-03-07 The Regents Of The University Of California Novel antiprion compounds
CN103058949A (zh) 2011-10-18 2013-04-24 华东理工大学 做为dhodh抑制剂的噻唑衍生物及其应用
CN103159695B (zh) 2011-12-08 2015-08-12 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
GB201307233D0 (en) 2013-04-22 2013-05-29 Vib Vzw Compounds and uses thereof
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素環式アミン誘導体
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Trpv4阻害活性を有する6員環誘導体
CN106109467B (zh) 2016-06-20 2020-04-17 中国药科大学 三类羧基取代芳香化合物在耐吡嗪酰胺结核病及结核病治疗中的医药用途
WO2018089902A1 (en) 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Diaminothiazole compounds, compositions and methods of use
WO2019133445A1 (en) * 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
SG11202012973RA (en) * 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
CN112654621B (zh) * 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
EP4013508A1 (en) * 2019-08-12 2022-06-22 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Nlrp3阻害剤
MX2022005376A (es) 2019-11-04 2022-05-19 Alector Llc Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.
AR120896A1 (es) 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CN120737188A (zh) 2020-04-24 2025-10-03 勃林格殷格翰国际有限公司 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
CA3180670A1 (en) 2020-04-24 2021-10-28 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation

Similar Documents

Publication Publication Date Title
JP2023504249A5 (cg-RX-API-DMAC7.html)
JP2023506532A5 (cg-RX-API-DMAC7.html)
JP2021526132A5 (cg-RX-API-DMAC7.html)
JP2021521194A5 (cg-RX-API-DMAC7.html)
JP2022532790A5 (cg-RX-API-DMAC7.html)
JP2022121594A5 (cg-RX-API-DMAC7.html)
US9192645B2 (en) Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US8435959B2 (en) Effective treatment of tumors and cancer with triciribine and related compounds
KR20220050143A (ko) Kras-관련 암 치료 방법
JP2019535749A5 (cg-RX-API-DMAC7.html)
JP2019519498A5 (cg-RX-API-DMAC7.html)
JP2021525768A5 (cg-RX-API-DMAC7.html)
JP2016528162A5 (cg-RX-API-DMAC7.html)
WO2008086005A1 (en) Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
JP2014097929A5 (cg-RX-API-DMAC7.html)
JP6620338B2 (ja) 低用量ナルトレキソンによるがん細胞の準備刺激
CN114867622A (zh) 涉及二芳基巨环化合物的组合疗法
JP2018515618A (ja) がん治療
US9486522B2 (en) Compositions including triciribine and trastuzumab and methods of use thereof
RU2019142694A (ru) Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний
TW201938543A (zh) 三取代之苯并三唑衍生物的使用方法
KR20170045237A (ko) 항-pd1 또는 항-pdl1 단클론성 항체와 조합된 시티딘 유사체의 경구 제제를 사용한 질환 또는 장애를 치료하는 방법
CN117956998A (zh) 治疗kras突变的癌症患者
JP2013528215A5 (cg-RX-API-DMAC7.html)
JP2023500857A (ja) 新規な化合物およびそれを含むがんの予防または治療用薬学組成物